JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

511.43 -1.3

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

511.43

Max

517.85

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+29.8% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.4B 12B
Vorige openingsprijs	512.73
Vorige sluitingsprijs	511.43

Nieuwssentiment

By Acuity

58%

42%

284 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 mei 2026, 21:36 UTC

Acquisities, Fusies, Overnames

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mei 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mei 2026, 18:37 UTC

Belangrijke Marktbewegers

Senseonic Shares Slide on Underwritten Offering Price

1 mei 2026, 16:46 UTC

Belangrijke Marktbewegers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 mei 2026, 19:57 UTC

Acquisities, Fusies, Overnames

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 mei 2026, 15:24 UTC

Winsten

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 mei 2026, 12:46 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 mei 2026, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

1 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 mei 2026, 20:42 UTC

Winsten

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mei 2026, 19:33 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 mei 2026, 19:33 UTC

Marktinformatie

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mei 2026, 19:18 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mei 2026, 19:13 UTC

Marktinformatie

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mei 2026, 18:36 UTC

Winsten

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mei 2026, 18:35 UTC

Winsten

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mei 2026, 18:28 UTC

Winsten

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mei 2026, 18:27 UTC

Marktinformatie

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mei 2026, 18:14 UTC

Acquisities, Fusies, Overnames

Barclays Completes Acquisition of Best Egg

1 mei 2026, 18:04 UTC

Winsten

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mei 2026, 17:43 UTC

Marktinformatie

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mei 2026, 17:37 UTC

Marktinformatie

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mei 2026, 17:30 UTC

Marktinformatie

Winsten

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mei 2026, 17:28 UTC

Marktinformatie

Winsten

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mei 2026, 17:21 UTC

Marktinformatie

Winsten

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mei 2026, 17:19 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mei 2026, 16:38 UTC

Marktinformatie

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mei 2026, 16:23 UTC

Acquisities, Fusies, Overnames

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

29.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 666.83 USD 29.8%

Hoogste 964 USD

Laagste 536 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

284 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.